ArticleTranslational lung cancer research2025
Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Compared with chemotherapy alone, the addition of atezolizumab to the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) improves the overall survival (OS), but the benefit remains limited. This study aims at investigating the factors influencing prognosis and to assess the effect of the number of induction chemotherapy cycles on treatment efficacy. Methods: We retrospectively analyzed the data of patients with ES-SCLC treated in five centers between March 2020 and September 2022. All 45 patients received first-line treatment with etoposide plus platinum combined with atezolizumab. The primary endpoints were progression-free survival (PFS) and OS in the total population and subpopulations based on the number of induction chemotherapy cycles. Least absolute shrinkage and selection operator (LASSO) regression were applied to identify the prognostic variables, and the effect of varying the number of induction chemotherapy cycles on the treatment efficacy was evaluated. Results: A total of 45 patients were enrolled in the study. The median PFS for the first-line treatment was 7 months, and the median OS was 17.6 months. The following 10 variables were analyzed using LASSO regression: gender, age, liver metastasis, bone metastasis, brain metastasis, number of first-line induction chemotherapy cycles, first-line immunotherapy maintenance, receipt of cross-line immunotherapy, chest radiotherapy, and brain radiotherapy. The analysis revealed that receiving ≥6 cycles of induction chemotherapy was the most important variable affecting prognosis and the only one significant [concordance index: 0.658; hazard ratio: 0.32 (95% confidence interval: 0.17-0.63)]. Patients who received ≥6 cycles of induction chemotherapy (n=25) had a longer median PFS (8 Conclusions: Receiving ≥6 cycles of induction chemotherapy significantly prolonged the median PFS and median OS of patients, highlighting its crucial factor influencing the efficacy of first-line atezolizumab combined with chemotherapy in patients with ES-SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.